These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 19355844)

  • 1. Responders to ChEI treatment of Alzheimer's disease show restitution of normal regional cortical activation.
    Venneri A; McGeown WJ; Shanks MF
    Curr Alzheimer Res; 2009 Apr; 6(2):97-111. PubMed ID: 19355844
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Response to cholinesterase inhibitors affects lifespan in Alzheimer's disease.
    Wattmo C; Londos E; Minthon L
    BMC Neurol; 2014 Sep; 14():173. PubMed ID: 25213579
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Established donepezil treatment modulates task relevant regional brain activation in early Alzheimer's disease.
    McGeown WJ; Shanks MF; Forbes-McKay KE; Waiter GD; Elrick I; Venneri MG; Venneri A
    Curr Alzheimer Res; 2010 Aug; 7(5):415-27. PubMed ID: 20455867
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Initial cognitive response to cholinesterase inhibitors and subsequent long-term course in patients with mild Alzheimer's disease.
    Droogsma E; van Asselt D; Diekhuis M; Veeger N; van der Hooft C; De Deyn PP
    Int Psychogeriatr; 2015 Aug; 27(8):1323-33. PubMed ID: 25779465
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-Term Response to Cholinesterase Inhibitor Treatment Is Related to Functional MRI Response in Alzheimer's Disease.
    Miettinen PS; Jauhiainen AM; Tarkka IM; Pihlajamäki M; Gröhn H; Niskanen E; Hänninen T; Vanninen R; Soininen H
    Dement Geriatr Cogn Disord; 2015; 40(5-6):243-55. PubMed ID: 26305064
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness and safety of cholinesterase inhibitors in elderly subjects with Alzheimer's disease: a "real world" study.
    Mossello E; Tonon E; Caleri V; Tilli S; Cantini C; Cavallini MC; Bencini F; Mecacci R; Marini M; Bardelli F; Sarcone E; Razzi E; Biagini CA; Masotti G
    Arch Gerontol Geriatr Suppl; 2004; (9):297-307. PubMed ID: 15207427
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial.
    Porsteinsson AP; Grossberg GT; Mintzer J; Olin JT;
    Curr Alzheimer Res; 2008 Feb; 5(1):83-9. PubMed ID: 18288936
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment effects of therapeutic cholinesterase inhibitors on visuospatial processing in Alzheimer's disease: a longitudinal functional MRI study.
    Thiyagesh SN; Farrow TF; Parks RW; Accosta-Mesa H; Hunter MD; Young C; Wilkinson ID; Woodruff PW
    Dement Geriatr Cogn Disord; 2010; 29(2):176-88. PubMed ID: 20215749
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Beneficial effect of cholinesterase inhibitor medications on recognition memory performance in mild to moderate Alzheimer's disease: preliminary findings.
    Crowell TA; Paramadevan J; Abdullah L; Mullan M
    J Geriatr Psychiatry Neurol; 2006 Mar; 19(1):13-5. PubMed ID: 16449754
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of cholinesterase inhibitors on visual attention in drivers with Alzheimer disease.
    Daiello LA; Ott BR; Festa EK; Friedman M; Miller LA; Heindel WC
    J Clin Psychopharmacol; 2010 Jun; 30(3):245-51. PubMed ID: 20473058
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Attenuation of functional hyperemia to visual stimulation in mild Alzheimer's disease and its sensitivity to cholinesterase inhibition.
    Janik R; Thomason LA; Chaudhary S; Dorr A; Scouten A; Schwindt G; Masellis M; Stanisz GJ; Black SE; Stefanovic B
    Biochim Biophys Acta; 2016 May; 1862(5):957-65. PubMed ID: 26521151
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Short-Term Response is not Predictive of Long-Term Response to Acetylcholinesterase Inhibitors in Old Age Subjects with Alzheimer's Disease: A "Real World" Study.
    Boccardi V; Baroni M; Smirne N; Clodomiro A; Ercolani S; Longo A; Ruggiero C; Bruni AC; Mecocci P
    J Alzheimers Dis; 2017; 56(1):239-248. PubMed ID: 27911323
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early- versus late-onset Alzheimer's disease in clinical practice: cognitive and global outcomes over 3 years.
    Wattmo C; Wallin ÅK
    Alzheimers Res Ther; 2017 Aug; 9(1):70. PubMed ID: 28859660
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patterns of brain activity during a semantic task differentiate normal aging from early Alzheimer's disease.
    McGeown WJ; Shanks MF; Forbes-McKay KE; Venneri A
    Psychiatry Res; 2009 Sep; 173(3):218-27. PubMed ID: 19683419
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer's disease.
    Morris JC; Cyrus PA; Orazem J; Mas J; Bieber F; Ruzicka BB; Gulanski B
    Neurology; 1998 May; 50(5):1222-30. PubMed ID: 9595967
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors of Response to Cholinesterase Inhibitors Treatment of Alzheimer's Disease: Date Mining from the TREDEM Registry.
    Gallucci M; Spagnolo P; Aricò M; Grossi E
    J Alzheimers Dis; 2016; 50(4):969-79. PubMed ID: 26836164
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Imaging treatment effects in Alzheimer's disease.
    Venneri A
    Magn Reson Imaging; 2007 Jul; 25(6):953-68. PubMed ID: 17446028
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prolonged cholinergic enrichment influences regional cortical activation in early Alzheimer's disease.
    McGeown WJ; Shanks MF; Venneri A
    Neuropsychiatr Dis Treat; 2008 Apr; 4(2):465-76. PubMed ID: 18728791
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mild versus moderate stages of Alzheimer's disease: three-year outcomes in a routine clinical setting of cholinesterase inhibitor therapy.
    Wattmo C; Minthon L; Wallin ÅK
    Alzheimers Res Ther; 2016 Feb; 8():7. PubMed ID: 26883213
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictive factors of clinical response to cholinesterase inhibitors in mild and moderate Alzheimer's disease and mixed dementia: a one-year naturalistic study.
    Miranda LF; Gomes KB; Silveira JN; Pianetti GA; Byrro RM; Peles PR; Pereira FH; Santos TR; Assini AG; Ribeiro VV; Tito PA; Matoso RO; Lima TO; Moraes EN; Caramelli P
    J Alzheimers Dis; 2015; 45(2):609-20. PubMed ID: 25589728
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.